Bayer AG (BAYGn.DE)
68.17EUR
4:35pm GMT
€2.62 (+4.00%)
€65.55
€65.18
€68.50
€65.09
4,044,916
3,532,122
€103.74
€58.34
Latest Key Developments (Source: Significant Developments)
Orion's And Bayer's Darolutamide Shows Substantial Efficacy And Favourable Safety Profile In Treatment Of Prostate Cancer In Aramis Trial
Feb 14 (Reuters) - Orion Oyj
Bayer Forms Research Alliance With Kyoto University
Jan 31 (Reuters) - Bayer AG
Petiq Inc Announces Amicable Legal Resolution
Jan 22 (Reuters) - PetIQ Inc
Bayer Sees No Impact Of Lilly Deal On Own Partnership With Loxo
Jan 7 (Reuters) - Bayer says on Loxo, Lilly deal::We can't comment on M&A activities of other companies.We don't see an impact to our contract with Loxo Oncology for the time being. Full Article
FDA Provides New Steps To Revise Bayer's Postmarket Surveillance Study On Essure Device
Dec 20 (Reuters) - U.S. Food and Drug Administration::FDA SAYS ANNOUNCES NEW STEPS TO STRENGTHEN LONG-TERM SAFETY OVERSIGHT OF ESSURE DEVICE FOLLOWING DISCONTINUATION OF ITS U.S. SALES.FDA SAYS PROVIDING AN UPDATE ON NEW STEPS TO REVISE AND STRENGTHEN BAYER'S POSTMARKET STUDY ON ESSURE DEVICE .FDA SAYS REGULATORY ACTIONS INCLUDES ITS DECISION TO TAKE STEP OF MAKING ESSURE A RESTRICTED DEVICE.FDA SAYS AS PART OF REVISED PROTOCOL FOR BAYER'S POSTMARKET SURVEILLANCE STUDY ON ESSURE, WOMEN IN STUDY WILL NOW BE FOLLOWED FOR 5 YEARS.FDA - AS PART OF REVISED PROTOCOL IT HAS WORKED WITH BAYER TO SEE THAT MANUFACTURER IMPLEMENTS SEVERAL APPROVED MODIFICATIONS TO POSTMARKET STUDY.FDA SAYS REQUIRING ADDITIONAL BLOOD TESTING OF PATIENTS ENROLLED IN FOLLOW-UP VISITS DURING BAYER'S POSTMARKET SURVEILLANCE STUDY ON ESSURE.FDA - REQUIRING BAYER TO CONTINUE TO ENROLL PATIENTS WHO MIGHT STILL OPT TO RECEIVE ESSURE IN ADVANCE OF ITS FULL DISCONTINUATION FROM U.S. MARKET.FDA - ALSO REQUIRING BAYER TO CONTINUE TO SUBMIT MORE FREQUENT REPORTS TO FDA ON ESSURE POSTMARKET STUDY'S PROGRESS AND RESULTS.FDA SAYS RECOGNIZES THAT BAYER IS HAVING CHALLENGES REACHING ESSURE POSTMARKET SURVEILLANCE STUDY'S INITIAL SAMPLE SIZE. Full Article
Bayer Statement On Updated Protocol For Postmarket Essure Study
Dec 20 (Reuters) - Bayer AG
Bayer Receives Approval In China For Endometriosis Treatment Visanne
Dec 20 (Reuters) - Bayer AG
Bayer Updates Betaseron Prescribing Information
Dec 17 (Reuters) - Bayer AG
German Chemicals Association Sees 2019 Sales Rising By 2.5 Pct
Dec 4 (Reuters) - German chemicals association VCI::SEES 2019 SALES +2.5 PERCENT, PRICES +1.0 PERCENT, PRODUCTION +1.5 PERCENT.SEES 2018 PRODUCTION +2.5 PERCENT (VERSUS PREVIOUS F'CAST OF +3.5 PERCENT), PRICES +2.0 PERCENT (VERSUS PREVIOUS F'CAST +1.5 PERCENT), SALES STILL AT +4.5 PERCENT. Full Article
Bayer: FDA Grants Breakthrough Device Designation To AI Software For CTEPH Pattern Recognition
Dec 3 (Reuters) - Bayer AG
Bayer gains full Vitrakvi rights from Eli Lilly's Loxo
FRANKFURT German drugmaker Bayer took full control of Vitrakvi, a drug used against a variety of cancers driven by a rare genetic mutation, in a deal with from Eli Lilly's Loxo Oncology.
Earnings vs. 
Estimates